Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Lissata Therapeutics Full Year 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. As a reminder, this call is being recorded today, Thursday, February 27, 2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at Lissata. Please go ahead, sir. Thank you, operator, and good afternoon, everyone. Welcome to Lissata's full year 2024 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer. Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our full year 2024 financial results, which is available under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release or if you'd like to be added to the company's email distribution list, please subscribe to the email alerts on the company website or email me at jmendito at lasada.com. Before we begin, I'll remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lasada. I encourage you to review the company's filings with the Securities ...